It is a dual p110γ/p110δ inhibitor which has been shown to decrease viability and induce apoptosis and autophagy in BCR-ABL positive B-ALL when combined with imatinib or nilotinib [71]. The gene discussed is PIK3CD; the disease is acute lymphoblastic leukemia.